{
    "clinical_study": {
        "@rank": "84029", 
        "arm_group": [
            {
                "arm_group_label": "selumetinib 75mg (oral capsule fasted)", 
                "arm_group_type": "Experimental", 
                "description": "Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state."
            }, 
            {
                "arm_group_label": "selumetinib 75mg (oral capusle fed)", 
                "arm_group_type": "Experimental", 
                "description": "Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state."
            }
        ], 
        "brief_summary": {
            "textblock": "Study to assess the effect of food on the Pharmacokinetics of Selumetinib  (AZD6244;\n      ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers"
        }, 
        "brief_title": "To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Solid Tumours", 
        "detailed_description": {
            "textblock": "A randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the\n      Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886)\n      (Hyd-Sulfate) in Healthy Volunteers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: 1. Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive)\n        and weigh at least 50 kg and no more than 100 kg (inclusive). 2. Must not have smoked or\n        used nicotine products within the previous 3 months. 3. Have a calculated creatinine\n        clearance (CrCL) greater than 50 mL/min using the Cockcroft-Gault formula.\n\n        Exclusion Criteria: 1. Current or past history of central serous retinopathy or retinal\n        vein thrombosis, intra-ocular pressure greater than 21 mmHg or uncontrolled glaucoma. 2.\n        Any clinically relevant abnormal findings in physical examination, hematology, clinical\n        chemistry, urinalysis, vital signs, or ECG at baseline in the opinion of the investigator.\n        3. History or presence of any clinically significant disease or disorder in the opinion of\n        the investigator. 4. Subjects of Japanese or non-Japanese Asian ethnicity. 5. Subjects\n        where any one parent or grandparent (maternal or paternal) is Japanese or non-Japanese\n        Asian (e.g., China, Taiwan, Korea, Philippines, Thailand, Vietnam and Malaysia). Asian\n        Indians are acceptable."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974349", 
            "org_study_id": "D1532C00069"
        }, 
        "intervention": {
            "arm_group_label": [
                "selumetinib 75mg (oral capsule fasted)", 
                "selumetinib 75mg (oral capusle fed)"
            ], 
            "description": "Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.", 
            "intervention_name": "selumetinib (oral)", 
            "intervention_type": "Drug", 
            "other_name": "AZD6244"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Phase I, healthy, pharmacokinetics, food effect.", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years", 
        "other_outcome": {
            "description": "Assessments performed during each of the 2 treatments", 
            "measure": "Safety variables (adverse events, physical examinations, ophthalmologic assessments, vital signs, clinical laboratory assessments, and 12 lead electrocardiograms)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline (Day-1) up to Day 24"
        }, 
        "overall_official": {
            "affiliation": "Quintiles 6700 W 115th Street, Kansas, US", 
            "last_name": "Eleanor Lisbon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Curve taken during each of the 2 treatments", 
            "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib, by assessment of maximum plasma concentration (Cmax)", 
            "safety_issue": "No", 
            "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974349"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib, by assessment of the area under the plasma concentration-time curve from time zero to infinity (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib, by assessment of the area under the plasma concentration-time curve from time zero to the time of the last measurable concentration AUC(0-t)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib, by assessment of area under the plasma concentration-time curve from time zero to 12 hours postdose AUC (0-12)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib, by assessment of time to Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib by assessment of apparent systemic plasma clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib by assessment of apparent volume at distribution equilibrium, mean residence time (MRT)*CL/F (Vss/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib by assessment of apparent volume at distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib by assessment of terminal half-life (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib by assessment of terminal rate constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib by assessment of (MRT)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib by assessment of AUC metabolite to parent ratio, N-desmethyl selumetinib AUC/selumetinib (AUC MRAUC)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }, 
            {
                "description": "Curve taken during each of the 2 treatments", 
                "measure": "Pharmacokinetics of selumetinib and N desmethyl selumetinib by assessment of Cmax metabolite to parent ratio, N-desmethyl selumetinib Cmax/selumetinib Cmax (MRCmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}